On June 30, 2026 FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, reported that Founder and Chief Executive Officer, Pete O’Heeron, and Chief Scientific Officer, Hamid Khoja, Ph.D., will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference taking place June 30 – July 1, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The fireside chat is scheduled for 1:00 p.m. ET on June 30, 2026, and will be moderated by Matthew Caufield, Senior Research Healthcare Analyst at H.C. Wainwright & Co. FibroBiologics will be available for one-on-one meetings throughout the event.

For more information, please visit FibroBiologics’ website, email FibroBiologics at [email protected] or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.

(Press release, FibroBiologics, JUN 30, 2026, View Source [SID1234669021])